New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
04:55 EDTGWPH, GWPHGW Pharmaceuticals management to meet with Leerink
Meeting to be held in New York on July 10 hosted by Leerink.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
06:01 EDTGWPHGW Pharmaceuticals selloff yesterday an overreaction, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says shares of GW Pharmaceuticals sold off yesterday in response to an abstract posted for the American Epilepsy Society conference in December describing a single center's experience with Epidiolex for seizures. The results support the drug's potent activity in Dravet syndrome, but some investors have concern with the drop-out rate due to inactivity and the lower response rate compared to what has otherwise been described for Epidiolex, Schimmer told investors last night in a research note titled "Over-Reacting To A Tree When The Forest Remains In Good Shape." The dropout rate is likely a result of the center's "highly questionable" practice of stopping drug if seizure reduction doesn't reach 50%, while the lower response rate at one site shouldn't detract from a "much bigger, robust clinical experience spanning multiple centers," Schimmer argues. He reiterates an Overweight rating on GW with a $147 price target. The stock closed yesterday down $5.42 to $82.30.
November 19, 2015
15:33 EDTGWPHGW Pharmaceuticals drops 10% after epilepsy study abstract posted
The conclusion of the abstract, posted to the the site of the American Epilepsy Society, stated: "Add-on pure CBD was associated with more than 50% seizure reduction in one-third of patients at 3 months...Best results were obtained in patients with Dravet syndrome, although one experienced a severe increase in seizure frequency."
15:31 EDTGWPHAbstract for GW Pharmaceuticals epilepsys study posted to AES site
Subscribe for More Information
November 16, 2015
07:16 EDTGWPHHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).
November 10, 2015
10:23 EDTGWPHGW Pharmaceuticals participates in a conference call with Leerink
Subscribe for More Information
08:25 EDTGWPHLeerink lays out bull/bear cases for GW into Phase 3 data
Ahead of the results from the first Epidiolex Phase 3 study in Q1 of 2016, Leerink analyst Paul Matteis lays out his bull/bear cases for shares of GW Pharmaceuticals. Matteis sees four scenarios on the first Dravet Phase 3 data, which assumes the market is pricing in a 60% probability-of-success and perceives the first Phase 3 result as a surrogate for the program. He estimates 65% share upside on study success and greater than 30% effect size, 45% upside on study success and greater than 20% effect size, 40% downside if the effect size is in high teens and results are close to but miss statistical significance, and 80% downside on a small or negligible Epidiolex effect. The analyst believes the Phase 3 Epidiolex trials in Dravet/Lennox Gastaut syndrome are likely to succeed and he continues to model a 66% approval probability. Matteis has an Outperform rating on GW Pharmaceuticals with a $135 price target. The stock closed yesterday up $3.47 to $85.37.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use